ABRAM NUNN: Open Payments
NPI 1952730020 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,683 in 76 payments from 11 companies in 2025. Trend: 2023 $662 · 2024 $1,165 · 2025 $1,683
Food & beverage: $1,572Education: $111
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $300 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $274 |
| Alkermes, Inc. | 13 | $268 |
| Neurocrine BioSciences, Inc. | 9 | $238 |
| Teva Pharmaceuticals USA, Inc. | 9 | $213 |
| Axsome Therapeutics, Inc. | 4 | $104 |
| E.R. Squibb & Sons, L.L.C. | 5 | $91 |
| Janssen Pharmaceuticals, Inc | 3 | $91 |
| Lundbeck LLC | 2 | $64 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
Products named: CAPLYTA, REXULTI, ARISTADA, INGREZZA, Auvelity, UZEDY, ABILIFY ASIMTUFII, COBENFY.
Industry payments across CA — which companies pay providers there.
